Screening men at increased risk for prostate cancer diagnosis

Model estimates of benefits and harms

Roman Gulati, Heather H. Cheng, Paul H. Lange, Peter S. Nelson, Ruth Etzioni

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Guidelines for PSA screening in subgroups with increased risk of prostate cancer diagnosis due to race or genotype are underdeveloped. Our goal was to investigate types of increased prostate cancer risk and implications for targeted screening. Methods: We investigated computer simulation of subgroups with average and hypothetical increased risk(s) of onset of latent disease, progression, and/or cancer-specific death. For each subgroup, we predicted lifetime probabilities of overdiagnosis and life saved under more and less intensive PSA screening strategies. An application estimated risks of onset among BRCA1/2 mutation carriers in the Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls (IMPACT) study using maximum likelihood. Results: Our simulations implied PSA screening can save more lives among subgroups with increased risk than with average risk, but more intensive screening did not always improve harm-benefit trade-offs. IMPACT data were consistent with increased risks of onset among BRCA1 and BRCA2 mutation carriers [HR = 1.05; 95% confidence interval (CI), 0.63-1.59 and HR = 1.81; 95% CI, 1.14-2.78, respectively]. Our analysis suggests screening BRCA2 mutation carriers earlier and more frequently than the average-risk population, but a lower PSA threshold for biopsy is unlikely to improve outcomes. Conclusions: Effective screening in men with increased prostate cancer risk depends on the manner in which the risk is increased. More intensive screening is not always optimal. Impact: Guidelines for screening men at increased prostate cancer risk should consider the mechanism inducing the increased risk. Although the benefit of screening may be greater in men with increased risks, more intensive screening is not always appropriate.

Original languageEnglish (US)
Pages (from-to)222-227
Number of pages6
JournalCancer Epidemiology Biomarkers and Prevention
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2017
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Mutation
Guidelines
Confidence Intervals
Genetic Predisposition to Disease
Early Detection of Cancer
Computer Simulation
Disease Progression
Genotype
Biopsy

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Screening men at increased risk for prostate cancer diagnosis : Model estimates of benefits and harms. / Gulati, Roman; Cheng, Heather H.; Lange, Paul H.; Nelson, Peter S.; Etzioni, Ruth.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 26, No. 2, 01.02.2017, p. 222-227.

Research output: Contribution to journalArticle

Gulati, Roman ; Cheng, Heather H. ; Lange, Paul H. ; Nelson, Peter S. ; Etzioni, Ruth. / Screening men at increased risk for prostate cancer diagnosis : Model estimates of benefits and harms. In: Cancer Epidemiology Biomarkers and Prevention. 2017 ; Vol. 26, No. 2. pp. 222-227.
@article{46c08937235e42e1b0fa12f675379084,
title = "Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms",
abstract = "Background: Guidelines for PSA screening in subgroups with increased risk of prostate cancer diagnosis due to race or genotype are underdeveloped. Our goal was to investigate types of increased prostate cancer risk and implications for targeted screening. Methods: We investigated computer simulation of subgroups with average and hypothetical increased risk(s) of onset of latent disease, progression, and/or cancer-specific death. For each subgroup, we predicted lifetime probabilities of overdiagnosis and life saved under more and less intensive PSA screening strategies. An application estimated risks of onset among BRCA1/2 mutation carriers in the Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls (IMPACT) study using maximum likelihood. Results: Our simulations implied PSA screening can save more lives among subgroups with increased risk than with average risk, but more intensive screening did not always improve harm-benefit trade-offs. IMPACT data were consistent with increased risks of onset among BRCA1 and BRCA2 mutation carriers [HR = 1.05; 95{\%} confidence interval (CI), 0.63-1.59 and HR = 1.81; 95{\%} CI, 1.14-2.78, respectively]. Our analysis suggests screening BRCA2 mutation carriers earlier and more frequently than the average-risk population, but a lower PSA threshold for biopsy is unlikely to improve outcomes. Conclusions: Effective screening in men with increased prostate cancer risk depends on the manner in which the risk is increased. More intensive screening is not always optimal. Impact: Guidelines for screening men at increased prostate cancer risk should consider the mechanism inducing the increased risk. Although the benefit of screening may be greater in men with increased risks, more intensive screening is not always appropriate.",
author = "Roman Gulati and Cheng, {Heather H.} and Lange, {Paul H.} and Nelson, {Peter S.} and Ruth Etzioni",
year = "2017",
month = "2",
day = "1",
doi = "10.1158/1055-9965.EPI-16-0434",
language = "English (US)",
volume = "26",
pages = "222--227",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Screening men at increased risk for prostate cancer diagnosis

T2 - Model estimates of benefits and harms

AU - Gulati, Roman

AU - Cheng, Heather H.

AU - Lange, Paul H.

AU - Nelson, Peter S.

AU - Etzioni, Ruth

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background: Guidelines for PSA screening in subgroups with increased risk of prostate cancer diagnosis due to race or genotype are underdeveloped. Our goal was to investigate types of increased prostate cancer risk and implications for targeted screening. Methods: We investigated computer simulation of subgroups with average and hypothetical increased risk(s) of onset of latent disease, progression, and/or cancer-specific death. For each subgroup, we predicted lifetime probabilities of overdiagnosis and life saved under more and less intensive PSA screening strategies. An application estimated risks of onset among BRCA1/2 mutation carriers in the Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls (IMPACT) study using maximum likelihood. Results: Our simulations implied PSA screening can save more lives among subgroups with increased risk than with average risk, but more intensive screening did not always improve harm-benefit trade-offs. IMPACT data were consistent with increased risks of onset among BRCA1 and BRCA2 mutation carriers [HR = 1.05; 95% confidence interval (CI), 0.63-1.59 and HR = 1.81; 95% CI, 1.14-2.78, respectively]. Our analysis suggests screening BRCA2 mutation carriers earlier and more frequently than the average-risk population, but a lower PSA threshold for biopsy is unlikely to improve outcomes. Conclusions: Effective screening in men with increased prostate cancer risk depends on the manner in which the risk is increased. More intensive screening is not always optimal. Impact: Guidelines for screening men at increased prostate cancer risk should consider the mechanism inducing the increased risk. Although the benefit of screening may be greater in men with increased risks, more intensive screening is not always appropriate.

AB - Background: Guidelines for PSA screening in subgroups with increased risk of prostate cancer diagnosis due to race or genotype are underdeveloped. Our goal was to investigate types of increased prostate cancer risk and implications for targeted screening. Methods: We investigated computer simulation of subgroups with average and hypothetical increased risk(s) of onset of latent disease, progression, and/or cancer-specific death. For each subgroup, we predicted lifetime probabilities of overdiagnosis and life saved under more and less intensive PSA screening strategies. An application estimated risks of onset among BRCA1/2 mutation carriers in the Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls (IMPACT) study using maximum likelihood. Results: Our simulations implied PSA screening can save more lives among subgroups with increased risk than with average risk, but more intensive screening did not always improve harm-benefit trade-offs. IMPACT data were consistent with increased risks of onset among BRCA1 and BRCA2 mutation carriers [HR = 1.05; 95% confidence interval (CI), 0.63-1.59 and HR = 1.81; 95% CI, 1.14-2.78, respectively]. Our analysis suggests screening BRCA2 mutation carriers earlier and more frequently than the average-risk population, but a lower PSA threshold for biopsy is unlikely to improve outcomes. Conclusions: Effective screening in men with increased prostate cancer risk depends on the manner in which the risk is increased. More intensive screening is not always optimal. Impact: Guidelines for screening men at increased prostate cancer risk should consider the mechanism inducing the increased risk. Although the benefit of screening may be greater in men with increased risks, more intensive screening is not always appropriate.

UR - http://www.scopus.com/inward/record.url?scp=85013665683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013665683&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-16-0434

DO - 10.1158/1055-9965.EPI-16-0434

M3 - Article

VL - 26

SP - 222

EP - 227

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 2

ER -